Hormone Therapy

Hormone therapy was associated with an improved weight-loss response for postmenopausal women with overweight or obesity treated with semaglutide, according to cohort study results published in Menopause.

Curriculums that paired several podcast episodes with case-based classroom discussions improved preparation and knowledge on menopause among OB/GYN, family medicine and internal medicine specialists, researchers reported in Menopause.

One-third of transgender and gender-diverse individuals on testosterone will experience at least one breakthrough bleeding episode, even after their first year of use, researchers reported in the American Journal of Obstetrics and Gynecology.

The FDA approved a second pulsed field ablation system for the treatment of paroxysmal atrial fibrillation based on real-world data from the MANIFEST-17K registry and positive findings from the pivotal ADVENT clinical trial.

The first Friday in February is Wear Red Day. In support of increasing awareness of women’s heart health, Healio | Cardiology Today compiled a list of recent news and updates on women and CVD research.

For women experiencing disruptive, bothersome hot flashes, the use of menopausal hormone therapy — a one-time standard but later feared treatment option — is far from straightforward.

Transgender girls see most of their body composition changes occur during puberty suppression, whereas transgender boys experience greater body composition changes during gender-confirming testosterone therapy, according to study data.

Menarche after the age of 14 years, or going through menopause before 45 years of age, are among the hormonal and reproductive factors that increase the risk for rheumatoid arthritis, according to data published in RMD Open.

Transgender and gender-diverse individuals reported experiencing rejection and discrimination due to acne, as well as unique barriers to acne care, according to study results published in JAMA Dermatology.

Fezolinetant 45 mg once daily was statistically significantly more effective in reducing moderate to severe vasomotor symptom frequency compared with other nonhormonal — but not hormone-based — therapies in the U.S., researchers reported.